<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="97303">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01715857</url>
  </required_header>
  <id_info>
    <org_study_id>P13-934</org_study_id>
    <nct_id>NCT01715857</nct_id>
  </id_info>
  <brief_title>Clinical Practice of Inhalation Anesthesia With Sevoflurane in China</brief_title>
  <official_title>A Multicenter Registry on the Clinical Practice of Inhalation Anesthesia With Sevoflurane in China</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AbbVie (prior sponsor, Abbott)</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AbbVie</source>
  <oversight_info>
    <authority>China: Food and Drug Administration</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      Until recently, there was a lack of understanding and consensus among Chinese
      anesthesiologists how they should practice general anesthesia with volatile anesthetics,
      since there was no standard of inhalation practice. In August 2011, the Anesthesiology
      branch of Chinese Medical Association launched the first version of Chinese Consensus of
      Standard Clinical Practice for Inhalation Anesthesia (Consensus) in order to standardize the
      practice in China.

      The proposed registry is aimed to evaluate the current inhalation practice, one year after
      the Consensus has been released, and related patient outcome.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2012</start_date>
  <completion_date type="Actual">July 2013</completion_date>
  <primary_completion_date type="Actual">July 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Case-Only, Time Perspective: Prospective</study_design>
  <primary_outcome>
    <measure>Anesthesiologist satisfaction with the anesthesia recorded at the end of the operation using a Numeric Analog Scale (NAS)</measure>
    <time_frame>Within 24 hours</time_frame>
    <safety_issue>No</safety_issue>
    <description>Anesthesiologist satisfaction with the anesthesia will be recorded at the end of the operation using a Numeric Analog Scale (NAS) from 0 (not satisfied at all) to 10 (completely satisfied)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Patient satisfaction with the anesthesia recorded at 24 hours after the end of the operation using a Numeric Analog Scale (NAS)</measure>
    <time_frame>Within 48 hours</time_frame>
    <safety_issue>No</safety_issue>
    <description>Patient satisfaction with the anesthesia will be recorded approximately 24 hours after the end of the operation using a Numeric Analog Scale (NAS) from 0 (not satisfied at all) to 10 (completely satisfied)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to eye opening</measure>
    <time_frame>Every minute after cessation of anesthesia until the patient open his/her eyes, up to 80 minutes</time_frame>
    <safety_issue>No</safety_issue>
    <description>After cessation of anesthesia, the investigators lightly tapped on the patients forehead or shoulder and asked the patients to open their eyes. This process is repeated approximately every minute until eye opening occurred.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to extubation</measure>
    <time_frame>Every minute after cessation of anesthesia until tracheal extubation occurs, up to 80 minutes</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cost of anesthetics</measure>
    <time_frame>Anesthetic duration between 1 to 5 hours</time_frame>
    <safety_issue>No</safety_issue>
    <description>Cost of anesthetics is the sum of the cost of sevoflurane and other anesthetics including narcotics and muscle relaxants. Cost of sevoflurane = unit price of sevoflurane x used volume of sevoflurane. Cost of other anesthetics = unit price of anesthetics x total volume of anesthetics in the ampoule.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">4100</enrollment>
  <condition>Anesthesia, General</condition>
  <arm_group>
    <arm_group_label>Chinese Patients Requiring Surgery with Anesthesia</arm_group_label>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Chinese patients undergoing surgery require general anesthesia (sevoflurane) with
        endotracheal intubation or laryngeal mask.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Man or woman, aged from 18 to 70 years old.

          2. ASA (American society of anesthesiologists) physical status: I, II and III.

          3. Surgery requiring sevoflurane anesthesia with endotracheal intubation or LMA
             (laryngeal mask).

          4. The type of surgery is either general surgery, or orthopedics, or gynecology.

          5. The duration of anesthesia ranges from 1 to 5 hours.

        Exclusion Criteria:

          1. History of clinically significant cardiovascular, pulmonary, renal, hepatic or
             central nervous system or muscle disease.

          2. Known hypersensitivity or history of unusual response to any halogenated anesthetics.

          3. Personal or familial history of malignant hyperthermia.

          4. Female patients who are either pregnant or breast feeding.

          5. General anesthesia is administered with total intravenous anesthesia (TIVA) of
             propofol or sevoflurane maintenance combined with propofol continuous infusion during
             maintenance.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yue  Kang, MD</last_name>
    <role>Study Director</role>
    <affiliation>AbbVie</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 84316</name>
      <address>
        <city>Beijing</city>
        <zip>100044</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 84317</name>
      <address>
        <city>Beijing</city>
        <zip>100000</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 84320</name>
      <address>
        <city>Beijing</city>
        <zip>100730</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 86755</name>
      <address>
        <city>Beijing</city>
        <zip>100029</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 96155</name>
      <address>
        <city>Beijing</city>
        <zip>100191</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 84321</name>
      <address>
        <city>Changchuan, Jining</city>
        <zip>130031</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 86754</name>
      <address>
        <city>Changchun, Jining</city>
        <zip>130033</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 86764</name>
      <address>
        <city>Changsha, Hunan</city>
        <zip>410008</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 86767</name>
      <address>
        <city>Changsha, Hunan</city>
        <zip>410013</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 100206</name>
      <address>
        <city>Chengdu</city>
        <zip>610041</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 86762</name>
      <address>
        <city>Chongqing</city>
        <zip>400042</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 102457</name>
      <address>
        <city>Guangzhou</city>
        <zip>511400</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 100095</name>
      <address>
        <city>Guangzhou</city>
        <zip>510655</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 106416</name>
      <address>
        <city>Guangzhou</city>
        <zip>510405</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 84337</name>
      <address>
        <city>Guangzhou, Guangdong</city>
        <zip>510515</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 84333</name>
      <address>
        <city>Guangzhou, Guangdong</city>
        <zip>510010</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 84338</name>
      <address>
        <city>Guangzhou, Guangdong</city>
        <zip>510030</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 84334</name>
      <address>
        <city>Harbin, Heilongjiang</city>
        <zip>150081</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 86759</name>
      <address>
        <city>Jinan, Shandong</city>
        <zip>250014</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 84318</name>
      <address>
        <city>Kunming, Yunnan</city>
        <zip>650032</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 86757</name>
      <address>
        <city>Kunming, Yunnan</city>
        <zip>650101</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 84336</name>
      <address>
        <city>Lanzhou, Gansu</city>
        <zip>730000</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 84322</name>
      <address>
        <city>Lanzhou, Gansu</city>
        <zip>730030</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 86761</name>
      <address>
        <city>Nanchang, Jiangxi</city>
        <zip>330006</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 102455</name>
      <address>
        <city>Qingdao</city>
        <zip>266011</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 78434</name>
      <address>
        <city>Shanghai</city>
        <zip>200025</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 86073</name>
      <address>
        <city>Shanghai</city>
        <zip>200127</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 84342</name>
      <address>
        <city>Shanghai</city>
        <zip>200438</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 84314</name>
      <address>
        <city>Shenyang, Liao Ning</city>
        <zip>110042</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 84319</name>
      <address>
        <city>Shijiazhuang Hebei</city>
        <zip>500011</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 95295</name>
      <address>
        <city>Tianjin</city>
        <zip>300162</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 100207</name>
      <address>
        <city>Tianjin</city>
        <zip>300052</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 86760</name>
      <address>
        <city>Wuhan, Hubei</city>
        <zip>430022</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 86766</name>
      <address>
        <city>Zhengzhou, Henan</city>
        <zip>450000</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 86763</name>
      <address>
        <city>Zhengzhou, Henan</city>
        <zip>450008</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 86769</name>
      <address>
        <city>Zunyi, Guizhou</city>
        <zip>563099</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <link>
    <url>http://rxabbvie.com</url>
  </link>
  <verification_date>July 2013</verification_date>
  <lastchanged_date>July 29, 2013</lastchanged_date>
  <firstreceived_date>September 2, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Economics, Pharmaceutical</keyword>
  <keyword>Physician's Practice Patterns</keyword>
  <keyword>Chinese</keyword>
  <keyword>Sevoflurane</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Anesthetics</mesh_term>
    <mesh_term>Sevoflurane</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
